A Multicenter, Randomized, Open-label, Phase II Clinical Study to Evaluate the Efficacy and Safety of Brivanib Alaninate (ZL-2301) Combined With Best Supportive Care (BSC) and Pharmacokinetic Profiles of Brivanib Alaninate in Patients With Advanced Hepatocellular Carcinoma (HCC) Failed or Intolerant of Standard Systemic Chemotherapy and/or Sorafenib
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Brivanib alaninate (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors ZAI Lab
- 28 Jan 2019 Planned End Date changed from 10 May 2019 to 1 Dec 2019.
- 28 Jan 2019 Planned primary completion date changed from 31 Jul 2018 to 31 Oct 2019.
- 26 Sep 2018 According to a Zai Lab media release, interim results from this trial were presented at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) on Sept. 22, 2018, at the Xiamen International Conference and Exhibition Center (XICEC).